ERBB2 and cancer: TNBC, known for its aggressive nature and lack of targeted therapies, has a strong counterpart in canines, where many malignant tumors exhibit low ER, PR, and HER2 expression, mirroring the poor prognosis of human TNBC (Namagerdi et al. 2020).